First Time Loading...

Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 4.74 USD -1.25% Market Closed
Updated: May 1, 2024

Intrinsic Value

OCUL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. [ Read More ]

The intrinsic value of one OCUL stock under the Base Case scenario is 2.28 USD. Compared to the current market price of 4.74 USD, Ocular Therapeutix Inc is Overvalued by 52%.

Key Points:
OCUL Intrinsic Value
Base Case
2.28 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ocular Therapeutix Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling OCUL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ocular Therapeutix Inc

Provide an overview of the primary business activities
of Ocular Therapeutix Inc.

What unique competitive advantages
does Ocular Therapeutix Inc hold over its rivals?

What risks and challenges
does Ocular Therapeutix Inc face in the near future?

Has there been any significant insider trading activity
in Ocular Therapeutix Inc recently?

Summarize the latest earnings call
of Ocular Therapeutix Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ocular Therapeutix Inc.

Provide P/S
for Ocular Therapeutix Inc.

Provide P/E
for Ocular Therapeutix Inc.

Provide P/OCF
for Ocular Therapeutix Inc.

Provide P/FCFE
for Ocular Therapeutix Inc.

Provide P/B
for Ocular Therapeutix Inc.

Provide EV/S
for Ocular Therapeutix Inc.

Provide EV/GP
for Ocular Therapeutix Inc.

Provide EV/EBITDA
for Ocular Therapeutix Inc.

Provide EV/EBIT
for Ocular Therapeutix Inc.

Provide EV/OCF
for Ocular Therapeutix Inc.

Provide EV/FCFF
for Ocular Therapeutix Inc.

Provide EV/IC
for Ocular Therapeutix Inc.

Show me price targets
for Ocular Therapeutix Inc made by professional analysts.

What are the Revenue projections
for Ocular Therapeutix Inc?

How accurate were the past Revenue estimates
for Ocular Therapeutix Inc?

What are the Net Income projections
for Ocular Therapeutix Inc?

How accurate were the past Net Income estimates
for Ocular Therapeutix Inc?

What are the EPS projections
for Ocular Therapeutix Inc?

How accurate were the past EPS estimates
for Ocular Therapeutix Inc?

What are the EBIT projections
for Ocular Therapeutix Inc?

How accurate were the past EBIT estimates
for Ocular Therapeutix Inc?

Compare the revenue forecasts
for Ocular Therapeutix Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ocular Therapeutix Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ocular Therapeutix Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ocular Therapeutix Inc compared to its peers.

Compare the P/E ratios
of Ocular Therapeutix Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ocular Therapeutix Inc with its peers.

Analyze the financial leverage
of Ocular Therapeutix Inc compared to its main competitors.

Show all profitability ratios
for Ocular Therapeutix Inc.

Provide ROE
for Ocular Therapeutix Inc.

Provide ROA
for Ocular Therapeutix Inc.

Provide ROIC
for Ocular Therapeutix Inc.

Provide ROCE
for Ocular Therapeutix Inc.

Provide Gross Margin
for Ocular Therapeutix Inc.

Provide Operating Margin
for Ocular Therapeutix Inc.

Provide Net Margin
for Ocular Therapeutix Inc.

Provide FCF Margin
for Ocular Therapeutix Inc.

Show all solvency ratios
for Ocular Therapeutix Inc.

Provide D/E Ratio
for Ocular Therapeutix Inc.

Provide D/A Ratio
for Ocular Therapeutix Inc.

Provide Interest Coverage Ratio
for Ocular Therapeutix Inc.

Provide Altman Z-Score Ratio
for Ocular Therapeutix Inc.

Provide Quick Ratio
for Ocular Therapeutix Inc.

Provide Current Ratio
for Ocular Therapeutix Inc.

Provide Cash Ratio
for Ocular Therapeutix Inc.

What is the historical Revenue growth
over the last 5 years for Ocular Therapeutix Inc?

What is the historical Net Income growth
over the last 5 years for Ocular Therapeutix Inc?

What is the current Free Cash Flow
of Ocular Therapeutix Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ocular Therapeutix Inc.

Financials

Balance Sheet Decomposition
Ocular Therapeutix Inc

Current Assets 232.2m
Cash & Short-Term Investments 195.8m
Receivables 26.2m
Other Current Assets 10.2m
Non-Current Assets 19.8m
PP&E 18.2m
Other Non-Current Assets 1.6m
Current Liabilities 34.9m
Accounts Payable 4.4m
Accrued Liabilities 30.3m
Other Current Liabilities 255k
Non-Current Liabilities 126m
Long-Term Debt 74.9m
Other Non-Current Liabilities 51.1m
Efficiency

Earnings Waterfall
Ocular Therapeutix Inc

Revenue
58.4m USD
Cost of Revenue
-5.3m USD
Gross Profit
53.2m USD
Operating Expenses
-135.5m USD
Operating Income
-82.4m USD
Other Expenses
1.6m USD
Net Income
-80.7m USD

Free Cash Flow Analysis
Ocular Therapeutix Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

OCUL Profitability Score
Profitability Due Diligence

Ocular Therapeutix Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

33/100
Profitability
Score

Ocular Therapeutix Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

OCUL Solvency Score
Solvency Due Diligence

Ocular Therapeutix Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
42/100
Solvency
Score

Ocular Therapeutix Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OCUL Price Targets Summary
Ocular Therapeutix Inc

Wall Street analysts forecast OCUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCUL is 15.81 USD with a low forecast of 11.11 USD and a high forecast of 25.2 USD.

Lowest
Price Target
11.11 USD
134% Upside
Average
Price Target
15.81 USD
234% Upside
Highest
Price Target
25.2 USD
432% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

OCUL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

OCUL Price
Ocular Therapeutix Inc

1M 1M
-45%
6M 6M
+49%
1Y 1Y
-23%
3Y 3Y
-74%
5Y 5Y
+27%
10Y 10Y
-64%
Annual Price Range
4.74
52w Low
2.08
52w High
10.93
Price Metrics
Average Annual Return 71.33%
Standard Deviation of Annual Returns 224.49%
Max Drawdown -91%
Shares Statistics
Market Capitalization 704.5m USD
Shares Outstanding 148 627 008
Percentage of Shares Shorted 10.31%

OCUL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

704.5m USD

Dividend Yield

0%

Description

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2014-07-25. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.

Contact

MASSACHUSETTS
Bedford
24 Crosby Dr
+17818953235.0
http://www.ocutx.com/

IPO

2014-07-25

Employees

228

Officers

President, CEO & Director
Mr. Antony Mattessich
Chief Financial Officer
Mr. Donald Notman Jr.
Chief Scientific Officer
Dr. Jeffrey S. Heier M.D.
Chief Medical Officer
Dr. Rabia Gurses Ozden M.D.
Executive Chairman
Dr. Pravin U. Dugel M.D.
Chief Operations Officer
Dr. Karen-Leigh Edwards M.B.A., Ph.D.
Show More
Chief Technology Officer
Dr. Peter K. Jarrett Ph.D.
General Counsel
Mr. Philip C. Strassburger Esq.
Vice President of Global Sales & Marketing
Mr. William H. Ransone II
Vice President of Human Resources
Ms. Tracy Smith
Show Less

See Also

Discover More
What is the Intrinsic Value of one OCUL stock?

The intrinsic value of one OCUL stock under the Base Case scenario is 2.28 USD.

Is OCUL stock undervalued or overvalued?

Compared to the current market price of 4.74 USD, Ocular Therapeutix Inc is Overvalued by 52%.